{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:45:39Z","timestamp":1762508739659,"version":"3.40.4"},"reference-count":7,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2022]]},"abstract":"<b><i>Background:<\/i><\/b> Elderly patients with extensive-disease small-cell lung cancer (ED-SCLC) have a high risk of chemotherapy toxicity due to multiple comorbidities and poor performance status. Although dose modification is often used to avoid toxicity in elderly patients with ED-SCLC, there is little data on the effect of initial dose-reduced chemotherapy on survival outcomes. <b><i>Methods and Patients:<\/i><\/b> We retrospectively reviewed 100 elderly patients (\u226570 years) with ED-SCLC who received first-line etoposide plus platinum chemotherapy between January 2006 and December 2020. <b><i>Results:<\/i><\/b> The median age was 74 years. Eighty-nine patients (89%) had a history of smoking, and 38 (38%) had chronic lung disease. Thirty-four patients (34%) received dose-reduced etoposide plus platinum in the first cycle. The dose-reduced group had significantly higher age, lower body mass index, and poor Eastern Cooperative Oncology Group Performance Score. There were no significant differences in survival outcomes between the dose-reduced and full-dose chemotherapy (median overall survival [OS], 4.9 vs. 6.5 months, <i>p<\/i> = 0.440; median progression-free survival [PFS], 3.7 vs. 4.6 months, <i>p<\/i> = 0.272). In multivariate analyses, DR in the first cycle (hazard ratio 0.519, 95% CI: 0.269\u20131.000, <i>p<\/i> = 0.050) was significantly associated with OS. Following a subgroup analysis of 59 patients who received minimum four cycles, no significant differences in survival outcomes between the two groups (median OS, 10.9 vs. 9.4 months, <i>p<\/i> = 0.817; median PFS, 6.3 vs. 6.5 months, <i>p<\/i> = 0.902) were noted. <b><i>Conclusions:<\/i><\/b> The dose-reduced chemotherapy with first-line etoposide plus platinum had non-inferior survival outcomes compared to the full-dose chemotherapy in elderly patients with ED-SCLC. <\/jats:p>","DOI":"10.1159\/000524476","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T21:00:38Z","timestamp":1649365238000},"page":"313-319","source":"Crossref","is-referenced-by-count":4,"title":["Dose Modification of Etoposide plus Platinum in Elderly Patients with Extensive-Disease Small-Cell Lung Cancer"],"prefix":"10.1159","volume":"100","author":[{"given":"Hyera","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehyun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi Hwa","family":"Heo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keon Uk","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-3051"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2018.01.16"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/crj.12632"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2009.162982"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2009.05.002"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2010.03.023"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.012492"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/524476","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/524476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:02:55Z","timestamp":1745424175000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000524476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":7,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,5,23]]},"published-print":{"date-parts":[[2022,5,31]]}},"URL":"https:\/\/doi.org\/10.1159\/000524476","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"type":"print","value":"0030-2414"},{"type":"electronic","value":"1423-0232"}],"subject":[],"published":{"date-parts":[[2022]]}}}